

## Q1 2025 Investor Call

May 13, 2025



### Cautionary Statements Regarding Forward-Looking Information

This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at

http://www.bayer.com/

The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


*Health for all, Hunger for none* 





BILL ANDERSON Chief Executive Officer





Confirming Full Year Outlook at Constant Currencies – Monitoring Geopolitical Developments

## Executing with Full Force on All Strategic Priorities



*Health for all, Hunger for none* 





WOLFGANG NICKL Chief Financial Officer



in €bn	Q1 2024	Q1 2025	$\Delta$ % yoy	
Net Sales	13.8	13.7	<b>0% сра</b> (0% гер)	Currency headwind of €0.1bn
<b>EBITDA</b> before special items	4.4	4.1	-7%	Lower Crop Science and Reconciliation, partly offset by higher Pharmaceuticals result; currency headwind of €0.2bn
<b>Core EPS</b> (in €)	2.82	2.49	-12%	Lower EBITDA before special items
Free Cash Flow	-2.6	-1.5		Including advance payments and change in factoring
Net Financial Debt	37.5	34.3	-9%	Focused capital allocation towards debt reduction

cpa = currency and portfolio adjusted, rep = as reported, core EPS = core earnings per share (cont. operations)

## Q1 2025: Results Weighed by Regulatory Challenges and Phasing Effects

### **Crop Science**

in€bn	Q1 2024	Q1 2025	$\Delta$ yoy
Net Sales	7.9	7.6	<b>-3% сра</b> (-4% rep)
Volume			-3%
Price			0%
FX			-1%
Portfolio			0%
<b>EBITDA</b> before special items	2.8	2.6	-10%
EBITDA Margin before special items	36.0%	33.7%	

- Core Business
  - Seeds & Traits driven by decline in soybeans and cotton due to US dicamba label vacatur, as well as corn volume phasing to Q2 following strategic change of distribution network
  - Core Crop Protection resulting from higher non-glyphosate herbicide volumes, partially offset by lower insecticide volumes due to expiration of Movento registration in EU
- **Glyphosate** with volumes down 9% due to phasing into subsequent quarters and price -1%
- Lower EBITDA margin primarily driven by decline in high margin sales due to regulatory impacts and corn sales phasing; partially offset by cost efficiency savings

-31%

€0.6bn

+6%

€2.4bn

### Q1 2025: Growth Across the Portfolio More Than Offsetting Xarelto Decline

### **Pharmaceuticals**

BAYER

9


in€bn	Q1 2024	Q1 2025	$\Delta$ yoy	Q1 2025 Net Sales by Catego	<b>ry</b> (∆ % yoy cpa, €bn)
Net Sales	4.4	4.5	<b>+4% cpa</b> (+4% rep) +4%	A +80%	Xarelto
Price FX			+4% +1% 0%	€0.7bn	€0
Portfolio			0%		
EBITDA before special items	1.2	1.3	+12%	+5%	Base Business <sup>1</sup>
EBITDA Margin before special items	27.4%	29.5%		€0.8bn	€2

- Significant growth of launch products Nubeqa (+78%) and Kerendia (+87%) more than offsetting Xarelto headwinds ٠
- Solid performance of Eylea with increasing contribution of Eylea 8 mg •
- Base Business benefitting from strong growth in Radiology and Women's Health, as well as high demand for Aspirin Cardio, Adalat and contraceptives ٠ in China
- **Improved EBITDA margin** driven by business growth and continued efficiency gains •

## Q1 2025: Moderate Start to the Year

### **Consumer Health**

in €bn	Q1 2024	Q1 2025	$\Delta$ yoy
Net Sales	1.4	1.5	<b>+3% cpa</b> (+5% rep)
Volume			+2%
Price			+1%
FX			0%
Portfolio			+3%
EBITDA before special items	0.3	0.3	+3%
EBITDA Margin before special items	23.1%	22.8%	



- · Sales expansion in almost all categories with early signs of volume recovery
- Growth driven by Digestive Health and Pain & Cardio, supported by product launches; strong demand of Cough & Cold products in North America
  was counterbalanced by a soft start to the Allergy season
- Nutritionals decline impacted by discontinuation of the Care/of business and soft performance in China, while EMEA grew
- EBITDA margin affected by lower divestment income and higher investments behind brands and innovation, counterbalanced by improved gross margin and ongoing efficiencies

### Group Outlook Confirmed at Constant Currencies – Monitoring Geopolitical Developments and FX Volatility

in €bn	FY 2025 Outlook at constant FX <sup>1</sup> / ∆ yoy %	FX Estimate at month-end March <sup>2</sup>
Net Sales	<b>45.0 to 47.0</b> -3% to +1% <sup>3</sup>	~-0.5 ~ -1%pts
<b>EBITDA</b> before special items	<b>9.5 to 10.0</b> -6% to -1%	~-0.3 ~ -3%pts
<b>Core EPS</b> (in €)	4.50 to 5.00	~-0.25
Free Cash Flow	1.5 to 2.5	~-0.2
Net Financial Debt	31.0 to 32.0	~-0.5

- Geopolitical Environment: based on current status of tariff announcements and mitigation measures, impact expected to be managed within guidance
- Foreign Exchange Rates: main swing factor, additional headwind at latest spot rates

<sup>1</sup>Reflects our 2025 outlook at the average actual currencies for 2024; <sup>2</sup>Estimated FX impact: Actual Q1 FX impact plus for remainder of the year FX assumptions based on month-end March 2025 spot rates (1 EUR=) 1.08 USD, 6.22 BRL, 7.85 CNY, 1,156 ARS, 41.00 TRY. Impact is calculated as difference to constant currencies. <sup>3</sup>Currency and portfolio adjusted growth; excludes portfolio effect of ~€+0.2bn driven by Natsana acquisition (Consumer Health).

IIIIII Health for all, Hunger for none



Q&A Session

*IIIIII Health for all, Hunger for none* 



## APPENDIX Outlook 2025



updated

in €bn	FY 2024 Actuals as reported	FY 2025 Outlook at constant FX <sup>1</sup>	Estimated FX Impact <sup>2</sup>	
Net Sales	46.6	<b>45.0 to 47.0</b> -3% to +1% <sup>3</sup>	~-0.5 ~ -1%pts	(previously: not material)
<b>EBITDA</b> before special items	10.1	<b>9.5 to 10.0</b> -6% to -1%	~-0.3 ~ -3%pts	(previously: ~-0.2 / ~ -2%pts)
<b>Core EPS</b> (in €)	5.05	4.50 to 5.00	~-0.25	
Free Cash Flow	3.1	1.5 to 2.5	~-0.2	
Net Financial Debt	32.6	31.0 to 32.0	~-0.5	(previously: ~+0.2)

<sup>1</sup>Reflects our 2025 outlook at the average actual currencies for 2024; <sup>2</sup>Estimated FX impact: Actual Q1 FX impact plus for remainder of the year FX assumptions based on month-end March 2025 spot rates (1 EUR=) 1.08 USD, 6.22 BRL, 7.85 CNY, 1,156 ARS, 41.00 TRY. Impact is calculated as difference to constant currencies. <sup>3</sup>Currency and portfolio adjusted growth; excludes portfolio effect of ~€+0.2bn driven by Natsana acquisition (Consumer Health).

## Outlook 2025: Divisions

		FY 2024 Actuals as reported	FY 2025 Outlook at constant FX <sup>1</sup>	FY 2025 Outlook estimated FX impact <sup>2</sup>
	Net Sales	€22.3bn	-2% to +2% <sup>3</sup>	~-1%pt
Crop Science	EBITDA Margin (before special items)	19.4%	18% to 20%	~ -1%pt
R A	Net Sales	€18.1bn	-4% to -1%	~-1%pt
Pharmaceuticals	EBITDA Margin (before special items)	26.0%	23% to 26%	~ -1%pt
	Net Sales	€5.9bn	+2% to +5% <sup>4</sup>	~-1%pt
Consumer Health	EBITDA Margin (before special items)	23.3%	23% to 24%	not material

<sup>1</sup>Reflects our 2025 outlook at the average actual currencies for 2024; <sup>2</sup>Estimated FX impact: Actual Q1 FX impact plus for remainder of the year FX assumptions based on month-end March 2025 spot rates (1 EUR=) 1.08 USD, 6.22 BRL, 7.85 CNY, 1,156 ARS, 41.00 TRY. Impact is calculated as difference to constant currencies = at average actual currencies for 2024; <sup>3</sup>Core growth -2% to +2%, Glyphosate growth -4% to 0%. <sup>4</sup>Currency and portfolio adjusted growth; excludes portfolio effect of ~€+0.2bn driven by Natsana acquisition

15

## Outlook 2025: Modelling Considerations

in €bn	FY 2025 Outlook at constant FX <sup>1</sup>	
Portfolio effect in Sales	~+0.2	Portfolio effects driven by Natsana acquisition
Special Items (EBITDA)	-1.5 to -0.5	Special items (EBITDA) expected rather tow
Core Depreciation	-1.7 to -1.6	includes DSO related severances and litigation
Core Financial Result	-2.0 to -1.8	Reconciliation <sup>2</sup> (EBITDA before special item assumptions for long-term incentive provision
Core Tax Rate	24% to 26%	effects
<b>Reconciliation<sup>2</sup>:</b> (EBITDA before special items)	~ -0.5	<b>FX effect</b> on all items not material

<sup>1</sup>Reflects our 2025 outlook at the average actual currencies for 2024; <sup>2</sup>Reconciliation reported as "All Other Segments" and not allocated "Enabling Functions" and "Consolidation".

16

*IIIIII Health for all, <u>Hunger for none</u>* 



## **APPENDIX** Q1 2025



## Q1 2025: Core Net Income and Free Cash Flow

<u>[</u> € bn]	Q1 2024	Q1 2025
Net Sales	13.8	13.7
EBITDA before special items	4.4	4.1
Core depreciation	-0.4	-0.4
Core EBIT <sup>1</sup>	4.0	3.7
Core financial result (before special items)	-0.4	-0.4
Core EBT	3.6	3.3
Minorities / noncontrolling interest	0.0	0.0
Core tax rate	22.3%	25.1%
Core tax	-0.8	-0.8
Core Net income	2.8	2.4
Amortization & extraordinary depreciation	-0.7	-0.8
Special Items (EBITDA & Financial Result)	-0.3	-0.7
Tax Effect on Adjustments	0.2	0.3
Net income	2.0	1.3




[€ bn]	Q1 2024	Q1 2025
Reported EBITDA	4.2	3.5
Tax payments	-0.4	-0.3
Delta pensions	-0.1	-0.1
Gains/Losses Divestments	-0.1	0.0
Delta Working Capital	-5.7	-4.1
t/o Delta Inventories	0.6	0.5
t/o Delta Receivables	-4.8	-4.5
t/o Delta Payables	-1.2	-0.8
t/o Other Working Capital	-0.3	0.7
Operating Cash Flow <sup>2</sup>	-2.2	-1.0
Interest & dividends received	0.0	-0.1
CapEx <sup>3</sup>	-0.4	-0.4
Free cash flow	-2.6	-1.5

- → Trade Working Capital change in factoring, improved collections and timing of accounts payables
- → Other Working Capital: mainly driven by advance payments from Crop Science customers and litigation provisions

<sup>1</sup>Delta between "Core EBIT" and "EBIT before special items" mainly driven by regular amortization of intangible assets (see for "EBIT before special items" slide "Q1 2025: Key Financial Measures by Division"); <sup>2</sup>Net cash provided by (used in) operating activities (excluding Interest & dividends received); <sup>3</sup>Cash flow-relevant capital expenditures (without leasing).

## Q1 2025: Core EPS to EPS Bridge



## Q1 2025: Regulatory Challenges and Seed Phasing Weigh on Performance

#### **Crop Science**

BAYER

#### Sales by Key Category and Strategic Business Entity (€m)

	Q1 2024	Q1 2025	$\Delta$ <b>yoy</b> (cpa)
Seeds & Traits	4,573	4,328	-5%
Corn Seed & Traits	3,242	3,189	-2%
Soybean Seed & Traits	604	522	-14%
Cotton Seed & Traits	290	232	-20%
Vegetable Seeds	184	192	+6%
Other	253	193	-22%
Core Crop Protection <sup>1</sup>	2,669	2,661	+2%
Fungicides	935	916	+1%
Herbicides excl Gly	944	1,003	+8%
Insecticides	459	387	-12%
Other	331	355	+8%
Core Business	7,250	6,989	<b>-3%</b> (-1% price, -2% volume)
Glyphosate-based Herbicides <sup>2</sup>	665	591	<b>-10%</b> (-1% price, -9% volume)

**Corn S&T:** driven by volume phasing into Q2 due to strategic change in distribution network and lower pricing in LATAM; partially offset by growth in EMEA and APAC

Soy S&T: decline in North America due to dicamba label vacatur

**Cotton S&T:** decline in North America due to dicamba label vacatur

**Vegetable Seeds:** strong performance largely driven by price and volume in LATAM

**Fungicides:** volume recovery in EMEA, partially offset by pricing pressure

Herbicides excl. GLY: strong gains from higher volumes across all regions, partially offset by pricing pressure

**Insecticides:** lower volume in EMEA due to expiration of Movento registration in EU, partially offset by higher volume and price in LATAM


All Other: lower volumes across other seed portfolio, partially offset by higher SeedGrowth volume and price

**Glyphosate-based Herbicides:** due to phasing into subsequent quarters

Sales growth rates in Key Messages cpa = currency and portfolio adjusted. <sup>1</sup> excluding Glyphosate-based Herbicides, <sup>2</sup> Industrial Turf & Ornamental business outside the United States now reports under Glyphosate-based Herbicides. Prior year figure adjusted accordingly. /// Bayer Q1 2025 Investor Call /// May 13, 2025

## Strong Demand and Low Glyphosate Pricing Anticipated for 2025

Glyphosate



#### **Market Trends:**

- Global demand continues to remain strong with excess supply in China. High channel inventory in US from China due to prepositioning ahead of anticipated tariffs. Channel inventory across other markets remains consistent with historical levels.
- Generic Chinese glyphosate technical reference spot price continues to trend significantly below 15-year historical median.
   Despite potential tariffs, US pricing opportunities limited by utilization of low-cost inventories pre-positioned from China.

#### **Our Strategy:**

- Maintain supply for ~40% global glyphosate market, with focus on the over-the-top markets in the Americas
- > Maintain brand premium over generic glyphosate-based herbicides with agile and strategic pricing

> Distinctly steered in a competitive commodity market

## Q1 2025: Strong Growth of Launch Products, Eylea and Base Business More Than Offsetting Xarelto Decline

### Pharmaceuticals

BAYER

#### Sales by Key Category and Product (€m)

	Q1 2024	Q1 2025	$\Delta$ <b>yoy</b> (cpa)
Launches	370	676	+80%
Nubeqa	285	515	+78%
Kerendia	85	161	+87%
Eylea	782	815	+5%
Eylea 2mg	782	676	-
Eylea 8mg	0	139	-
Xarelto	926	633	-31%
<b>Base Business</b>	2,280	2,424	+6%
Radiology	502	543	+8%
Women's Health	680	773	+13%
IUD Family	293	352	+18%
Yaz Family	165	187	+14%
Other	222	234	+6%
Adempas	171	183	+6%
HEM Franchise	167	158	-6%
Aspirin Cardio	151	189	+26%
Adalat	127	145	+12%
Other	482	433	-10%

Nubeqa: strong growth across all regions, led by US and Europe
Kerendia: further strong growth momentum, especially in US and China
<b>Eylea:</b> continued growth driven by EU and Japan, supported by 8mg launches (incl. pre-filled syringe)
Xarelto: continued LoE-driven genericization in Japan, Europe and Russia, on top of ongoing at-risk launches in Europe
<b>Radiology:</b> Significant volume growth of Ultravist, continued strong growth of CT Fluid Delivery
IUD Family: significant growth in US, driven by increased demand
Yaz Family: growth largely driven by higher volumes in China
Adempas: high patient compliance continues to drive US sales expansion
<b>HEM Franchise:</b> continued competitive pressure weighing on volumes and prices
<b>Aspirin Cardio:</b> high demand in Q1 in China prior to expected VBP 10 implementation, driven by positive brand image
Adalat: growth mainly driven by hospital phasing effect in China

Sales growth rates in Key Messages cpa = currency and portfolio adjusted.

## Q1 2025: Growth Contribution From All Categories, Except Nutritionals

### **Consumer Health**

#### Sales by Category (€m)

	Q1 2024	Q1 2025	$\Delta$ <b>yoy</b> (cpa)
Dermatology	349	352	+2%
Nutritionals	335	351	-5%
Allergy & Cold	335	347	+2%
Digestive Health	222	252	+13%
Pain & Cardio	181	188	+7%
Other	10	9	-7%

**Dermatology:** Growth primarily driven by continuous strong demand for Bepanthen and Canesten, along with support from innovations such as KangWang in China

**Nutritionals**: Strong demand particularly for Supradyn in Europe offset by weaker performance in China and the discontinuation of the Care/of business in the US

Allergy & Cold: Strong demand of cold products in North America was counterbalanced by a soft start to the allergy season

**Digestive Health:** Growth supported by product launches, e.g. Iberogast in US, and by sustained supply stability

**Pain & Cardio:** Driven by product launches as well as by strong demand for Saridon in Asia Pacific and for Asprin Cardio in Europe and North America

Sales growth rates in Key Messages cpa = currency and portfolio adjusted.

### Q1 2025: Key Financial Measures by Division

	Crop Sc		Pharmac		Consume		Reconc		Grou	-
[€ million, if not specified]	Q1 24	Q1 25	Q1 24	Q1 25	Q1 24	Q1 25	Q1 24	Q1 25	Q1 24	Q1 25
Sales	7,907	7,580	4,358	4,548	1,432	1,499	68	111	13,765	13,738
Sales by region:										
Europe / Middle East / Africa	2,079	2,094	1,822	1,628	523	572	67	110	4,491	4,404
North America	4,122	3,869	1,110	1,399	528	554	0	0	5,760	5,822
Asia / Pacific	519	571	1,187	1,290	208	218	0	0	1,914	2,079
Latin America	1,187	1,046	239	231	173	155	1	1	1,600	1,433
Cost of goods sold <sup>1,2</sup>	-3,846	-3,917	-1,089	-1,073	-481	-495	-12	-68	-5,428	-5,553
Selling expenses <sup>1,2</sup>	-1,148	-1,050	-1,403	-1,409	-647	-661	18	-17	-3,180	-3,137
Research and development expenses <sup>1,2</sup>	-585	-609	-746	-769	-55	-60	11	-8	-1,375	-1,446
General administration expenses <sup>1</sup>	-176	-162	-194	-181	-39	-36	-128	-151	-537	-530
Other operating income / expenses <sup>1</sup>	-30	-55	42	-13	28	-2	14	-91	54	-161
EBIT before special items	2,122	1,786	968	1,103	238	245	-29	-224	3,299	2,911
EBIT margin before special items [%]	26.8%	23.6%	22.2%	24.3%	16.6%	16.3%	-42.6%	-201.8%	24.0%	21.2%
Special items	-59	-401	-96	-114	-9	-8	-43	-64	-207	-587
EBIT	2,063	1,386	872	989	229	237	-72	-288	3,092	2,324
Depreciation & Amortization <sup>1</sup>	727	771	226	239	93	97	67	67	1,113	1,174
EBITDA before special items	2,849	2,557	1,194	1,342	331	342	38	-157	4,412	4,085
EBITDA margin before special items [%]	36.0%	33.7%	27.4%	29.5%	23.1%	22.8%	55.9%	-141.4%	32.1%	29.7%
Special items	-60	-401	-95	-114	-9	-8	-43	-64	-207	-587
EBITDA	2,789	2,157	1,099	1,228	322	334	-5	-221	4,205	3,498
Operating cash flow, continuing <sup>3</sup>	-2,865	-2,406	809	1,161	219	405	-313	-175	-2,150	-1,015
Cash flow-relevant capital expenditures <sup>4</sup>	-210	-164	-178	-163	-26	-30	-32	-31	-446	-388

<sup>1</sup>Before special items; <sup>2</sup>Includes purchase price amortization (PPA) of €404m in COGS, €36m in selling expenses, €32m in R&D in 2025 and €356m in COGS, €43m in selling, €32m R&D in 2024, for Crop Science and Group; <sup>3</sup>Net cash provided by (used in) operating activities; <sup>4</sup>Cash flow-relevant capital expenditures (without leasing)

BAYER

*IIIIII Health for all, Hunger for none* 



## APPENDIX

Innovation

#### Not exhaustive

Blockbuster = >€0.5bn exp. PSP



### Crop Science: R&D Pipeline Annual Update - May 2025


### **Total PSP** ~€32bn

Biological

	Phase II	Phase III	Phase IV	Lifecycle management <sup>1</sup>	PSP <sup>2</sup>
Ξ	Corn LEP5	Corn HT5	Preceon Smart Corn – Biotech Trait <sup>3</sup>		
S			Corn LEP4		~€11bn
- T			CRW4		~€T1DN
တိ	Corn Annual Germpl	g precision breeding			
N	Soy IP4	Soy HT5 (6 Tolerances - Adds PPO)	Soy IP3	Trait extensions (e.g., geographic expansion into	
- Soy		APAC and Africa, event stacking)	CEL		
S&T			Vistive Gold Xtend	Enhancement of FieldView and continuous upgrades of digital features (e.g., next gen. seed	~€5bn
လ	Soy Annual Germpla	asm Upgrades and New Variety Launches – Leveraging	g precision breeding	placement and density tools)	
∋r⁴	Canola HT4	Sugarbeets 2nd Generation Herbicide Tolerance <sup>5</sup>		· · · · · · · · · · · · · · · · · · ·	
S&T - Other <sup>4</sup>		Cotton HT4 (5 Tolerances - Adds 2, HPPD & PPO)			646-
÷		Cotton IP4			~€4bn
S&	Wheat, Cotton, Canola/OSR, Veg, Rice Ann	nual Germplasm Upgrades and New Hybrid and Variety	/ Launches – Leveraging precision breeding		
9	New Herbicide	New Herbicide 💉	Icafolin A 🔶 🖛	Non-selective: Glyphosate	
HER		New Herbicide		Selective: Merlin Flexx/Adego, Balance Flexx, Convintro, New over-the-top HER, Council	~€6bn
		New Herbicide		Family, Ronstar One, Mesosulfuron	
	New Fungicide •	New Fungicide <sup>8</sup>		Nativo Plus, Fox Supra Continous enhancement of digital features (e.g.,	~€3bn
с В	New Fungicide			wheat disease management tool)	espin
<b>SNI</b>	New Insecticide		Plenexos	Vayego Duo, Fluopyram, New BLX-Containing Nematicide Mixture	~€2bn
			Ibisio	INS FUN ready mixture, Ladoran	
SGR <sup>10</sup>			New Seed Treatment	· · · · · ·	~€1bn
1. Show Potentia under S	I, 50% incremental; Expected to reach 30% of PSP by 2032, 80% &T and included in the peak sales potential by segment do not inc	of PSP by 2038 and remainder in 2039+; Note that products are lude projects funded by "Leaps by Bayer" investments 3. BASF of	s; incl. all advancements made in FY'24, updated May '25 2. PSP excluded from the pipeline PSP typically the year following launch collaboration 4. Includes seeds and traits, such as vegetables, cot ungicide 8. 3rd party collaboration 9. INS = Insecticide 10. SGR =	Projects listed  Developed with CropKey LEP = Lepidopter	tworm a Protection Protection

/// Bayer Q1 2025 Investor Call /// May 13, 2025

#### BAYER Pharmaceuticals: R&D Developments (since last update on March 5, 2025)



<sup>1</sup> Including Precision Cardiovascular, Nephrology & Acute Care

Oncology

Others

Cardiovascular+1

## BAYER ER

## Pharmaceuticals – Pipeline Overview<sup>1</sup> (as of May 02, 2025)

Phase I	Phase II	Phase III		
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)	Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088) // Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)	Darolutamide (AR Inhibitor)       # Adjuvant Prostate Cancer (DASL-HiCaP)		
DGKzeta Inhibitor (BAY 2965501)	Congestive Heart Failure rAAV Gene Therapy (AB-1002)	# Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)		
anerkitug (CCR8 Ab) (BAY 3375968)	// Congestive Heart Failure (GenePHIT)	Sevabertinib (HER2/mEGFR Inhibitor)		
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)	Anti-a2AP (BAY 3018250) # Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)	# Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)		
DGKalpha Inh (BAY 2862789) 🦂 🦂	Nurandociguat (sGC Activator Oral) (BAY 3283142) // Chronic Kidney Disease (ALPINE-1)	Finerenone (MR Antagonist)         // Non-diabetic Chronic Kidney Disease (FIND-CKD)		
225Ac-Pelgifatamab (BAY 3546828)	Parkinson's Disease rAAV Gene Therapy (AB-1005)	// Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)		
VVD STAT3 Inhibitor (VVD-130850, BAY 3630914) 🦂 🧲	// Parkinson's Disease (REGENERATE-PD)	Vericiguat (sGC Stimulator)       // Heart Failure (HFrEF) (VICTOR <sup>2</sup> )		
225Ac-PSMA-Trillium (BAY 3563254) 🛞 🥘		Asundexian (FXIa Inhibitor)		
SOS1 Inhibitor (BAY 3498264)		// 2º Stroke Prevention (OCEANIC-STROKE)		
PRMT5 Inhibitor (BAY 3713372)		Gadoquatrane (High Relaxivity Contrast Agent) # Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OBR)		
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171) 👗 🧲				
225Ac-GPC3 (BAY 3547926)		Oncology		
SEMA 3a (BAY 3401016) 5		Submissions Cardiovascular+3		
Anti-coagulant (BAY 3389934)		Darolutamide (AR Inhibitor) // US, EU, CN: Prostate Cancer (mHSPC)		
Atrial fibrillation		Immunology		
Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)		Finerenone (MR Antagonist)     Image: Constraint of the state of the s		
Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)		Elinzanetant (Neurokinin-1,3 Rec Antagonist) US, EU: Vasomotor Symptoms New molecular ent		
Pompe Disease rAAV Gene Therapy (ACTUS-101)		Aflibercept 8mg (VEGF-Inhibitor)		
LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)		# EU: Retinal Vein Occlusion		
GPR84 Antagonist (BAY 3178275)	A Protein Therapeutics	Cell Therapy 🛱 Contrast Agent 🛛 🦉 Genetic Medicine 🛛 🕅 Radionuclide Therapy 🙏 Small Mol		
BAY 2701250	3 Frotein merapeutics	Sen merapy 🕂 contrast Agent 🗶 Genetic medicine 🚫 Kadionucide merapy 🦂 Sugii Molecu		

/// Bayer Q1 2025 Investor Call /// May 13, 2025


28


https://www.bayer.com/en/pharma/development-pipeline

### Major R&D Milestones Expected Until End-2025



## Nubeqa Continues to Show Strong Uptake With Gains in All Regions







BAYER


Nubeqa continues to grow faster than the ARI<sup>2</sup> market in the US The mHSPC<sup>3</sup> launch continues to be a success in all markets, with particularly strong uptake in EMEA

Nubeqa is approved in more than 88 countries today (mHSPC approvals in 87 markets)

<sup>1</sup>Source: IQVIA, YTD January 2025 <sup>2</sup>ARI: Androgen Receptor Inhibitor <sup>3</sup>mHSPC: metastatic hormone sensitive prostate cancer

## Kerendia Demonstrates Continued Launch Uptake







 $(\Sigma)$ 


Solid sales growth momentum in the US, NBRx growth trending upward in CKD/T2D indication. HF indication launch anticipated in 2025, pending FDA approval.

Growing ex-US penetration in key regions and countries, with China, India and Mexico as strong growth drivers. FDA grants priority review for HF LVEF≥40% indication. Further regulatory submissions to health authorities conducted and ongoing.

<sup>1</sup>Source: This is based on information licensed from IQVIA: US Subnational NBRx for the period 11/21 to 03/25 US Market includes NBRx linked to T2D and CKD reflecting estimates of real-world activity. All rights reserved.

### Eylea Maintaining Market Leadership; Launch of 8mg Gaining Further Momentum







BAYER

32

Increasing momentum of Eylea 8mg with continued roll-outs across available markets and the launch of the OcuClick PFS<sup>2</sup>

Continued strong leadership in the anti-VEGF segment with stable market share  Unparalleled approved treatment interval of up to 5 months, EU application submitted for RVO indication on April 7

<sup>1</sup>Source: Company market data 1. MARS (IQVIA+GERS, NPI) value market share, 2 PFS: pre-filled syringe

*Health for all, Hunger for none* 



# Thank you!